Hepsin is down-regulated in gastric cancer and predicts a poor prognosis

Chinese Journal of Gastroenterology

Volumn 17, Issue 10, 2012, Pages 592-596

  Lei, Kefeng ^a,b   Liu, Bingya ^a   Zhang, Xiaoqing ^a   Jin, Xiaolong ^a   Guo, Yan ^a   Zhu, Zhenggang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Hepsin; Immunohistochemistry; Microarray analysis; Prognosis; Real time PCR; Stomach neoplasms

Indexed keywords

COMPLEMENTARY DNA; HEPSIN; MESSENGER RNA; PARAFFIN;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STOMACH CANCER;

EID: 84871118571     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1008-7125.2012.10.004     Document Type: Article

References (21)

1. Chau I, Norman A R, Cunningham D, et al. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data[J]. J Clin Oncol, 2004, 22 (12): 2395-2403.
2. Hohenberger P, Gretschel S. Gastric cancer[J]. Lancet, 2003, 362 (9380): 305-315.
3. Fidler I J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited[J]. Nat Rev Cancer, 2003, 3 (6): 453-458.
4. Chambers A F, Groom A C, MacDonald I C. Dissemination and growth of cancer cells in metastatic sites[J]. Nat Rev Cancer, 2002, 2 (8): 563-572.
5. Curran S, Murray G I. Matrix metalloproteinases in tumour invasion and metastasis[J]. J Pathol, 1999, 189 (3): 300-308.
6. Rawlings N D, Morton F R, Barrett A J. MEROPS: the peptidase database[J]. Nucleic Acids Res, 2006, 34 (Database issue): D270-D272.
7. 2006, 26 (2): 216-218.
8. 2006, 28 (2): 116-119.
9. Harvey J M, Clark G M, Osborne C K, et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer[J]. J Clin Oncol, 1999, 17 (5): 1474-1481.
10. Leytus S P, Loeb K R, Hagen F S, et al. A novel trypsin-like serine protease (hepsin) with a putative transmem-brane domain expressed by human liver and hepatoma cells[J]. Biochemistry, 1988, 27 (3): 1067-1074.
11. Somoza J R, Ho J D, Luong C, et al. The structure of the extracellular region of human hepsin reveals a serine protease domain and a novel scavenger receptor cysteine-rich (SRCR) domain[J]. Structure, 2003, 11 (9): 1123-1131.
12. Kazama Y, Hamamoto T, Foster D C, et al. Hepsin, a putative membrane-associated serine protease, activates human factor VII and initiates a pathway of blood coagulation on the cell surface leading to thrombin formation[J]. J Biol Chem, 1995, 270 (1): 66-72.
13. Aimes R T, Zijlstra A, Hooper J D, et al. Endothelial cell serine proteases expressed during vascular morphogenesis and angiogenesis[J]. Thromb Haemost, 2003, 89 (3): 561-572.
14. Tsuji A, Torres-Rosado A, Arai T, et al. Characterization of hepsin, a membrane bound protease[J]. Biomed Biochim Acta, 1991, 50 (4-6): 791-793.
15. Stephan C, Yousef G M, Scorilas A, et al. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer[J]. J Urol, 2004, 171 (1): 187-191.
16. Betsunoh H, Mukai S, Akiyama Y, et al. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma[J]. Cancer Sci, 2007, 98 (4): 491-498.
17. Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is over-expressed in ovarian cancer[J]. Cancer Res, 1997, 57 (14): 2884-2887.
18. Xing P, Li J G, Jin F, et al. Clinical and biological significance of hepsin overexpression in breast cancer[J]. J Investig Med, 2011, 59 (5): 803-810.
19. Matsuo T, Nakamura K, Takamoto N, et al. Expression of the serine protease hepsin and clinical outcome of human endometrial cancer[J]. Anticancer Res, 2008, 28 (1A): 159-164.
20. Kirchhofer D, Peek M, Lipari M T, et al. Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2[J]. FEBS Lett, 2005, 579 (9): 1945-1950.
21. Wittig-Blaich S M, Kacprzyk L A, Eismann T, et al. Matrix-dependent regulation of AKT in Hepsin-overexpressing PC3 prostate cancer cells[J]. Neoplasia, 2011, 13 (7): 579-589.